We came across a bullish thesis on Viking Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.'s share was trading at $29.30 as of February 9th.
[caption id="attachment_518884" align="aligncenter" width="750"]Viking Therapeutics (VKTX) has emerged as a compelling scientific and strategic play in the obesity and metabolic therapy space, particularly following Novo Nordisk’s approval of the Wegovy® Pill,...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.